Search results for " the metabolic syndrome"
showing 6 items of 6 documents
Small, dense low-density lipoproteins (LDL) are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome
2009
Summary Objective Small, dense low-density lipoproteins (LDL) are a feature of the metabolic syndrome (MS) but their predictive role still remains to be established. We performed a 2-year follow-up study in 124 subjects with MS (63 ± 6 years), as defined by the American Heart Association/National Heart, Lung and Blood Institute guidelines, to assess clinical and biochemical predictors of cerebro- and cardio-vascular events. Methods and results Beyond traditional cardiovascular risk factors, we measured LDL size and subclasses by gradient gel electrophoresis. Clinical events were registered in the 25% of subjects. At univariate analysis subjects with events had increased prevalence of elev…
Small, dense low-density lipoproteins are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome.
2008
Prediction of vascular events in subjects with subclinical atherosclerosis and the metabolic syndrome: the role of markers of inflammation.
2010
Prediction of cardio- and cerebro-vascular events in patients with subclinical carotid atherosclerosis and the metabolic syndrome.
2009
Managing the Cardiovascular Risk Associated with the Metabolic Syndrome
2014
Effects of Liraglutide on Metabolic Parameters and Carotid Intima-Media Thickness in Patients with The Metabolic Syndrome: A 12-Month Prospective Pil…
2014
Recent research indicates that therapy with the GLP-1 agonist liraglutide in patients with type 2 diabetes mellitus (T2DM) seems to have beneficial actions on blood pressure, lipids, and the atherosclerotic process, which may be independent of its effect on glucose metabolism. However, the effects of liraglutide in subjects with the metabolic syndrome (MetS) are largely unknown. Forty-nine subjects with the MetS (24 men and 25 women, age 65±10 yrs) diagnosed by the AHA/NHLBI criteria were included in a 12-month prospective study. All subjects had T2DM, were naïve to incretin-based therapies, and treated with metformin only. Liraglutide was added at a dose of 0.6 mg subcutaneously daily for …